The initial public offering (IPO) of Influx Healthtech, a prominent player in the healthcare-focused contract manufacturing sector, concludes its subscription period today, June 20, 2025. The SME IPO has garnered substantial interest from investors across all categories, resulting in significant oversubscription.
Subscription Status: A Robust Response
As of the latest available data on the final day of bidding, Influx Healthtech IPO has been remarkably oversubscribed. Retail individual investors (RIIs) have shown overwhelming enthusiasm, bidding multiple times their allotted quota. Non-institutional investors (NIIs), including high-net-worth individuals and corporate entities, have also demonstrated strong demand. Qualified Institutional Buyers (QIBs) have also subscribed to their portion, indicating confidence from institutional players.
While the final subscription figures will be released post-closure, early trends suggest a highly successful public issue for Influx Healthtech. This strong investor appetite underscores the market’s positive outlook on the company’s business model and growth prospects in the thriving healthcare and wellness sector.
Grey Market Premium (GMP) Today: Indicating a Healthy Listing
The Grey Market Premium (GMP) for Influx Healthtech IPO has remained positive and relatively stable throughout the bidding period. As of today, June 20, 2025, the GMP is reported to be around ₹38.
Considering the upper end of the IPO price band at ₹96 per equity share, a GMP of ₹38 suggests a potential listing price of approximately ₹134 per share. This indicates a healthy premium of around 39.58% over the issue price, signaling a favorable listing for investors. It’s crucial for investors to remember that GMP is an unofficial indicator based on speculative trading in the grey market and is subject to fluctuations. However, a consistent positive GMP often reflects strong market sentiment.
IPO Details and Company Overview
Influx Healthtech’s IPO is a book-building issue aiming to raise approximately ₹55.63 crore. The issue comprises a fresh issue of 46.94 lakh shares and an offer-for-sale (OFS) of 11 lakh shares. The price band for the IPO was fixed at ₹91 to ₹96 per equity share, with a face value of ₹10 per share. Retail investors could apply for a minimum lot size of 1200 shares, requiring an investment of ₹1,15,200.
Established in 2020, Influx Healthtech Limited specializes in contract development and manufacturing (CDMO) services for the healthcare sector. The company operates three manufacturing facilities in Thane, Maharashtra, and is known for its expertise in producing dietary and nutritional supplements, cosmetics, Ayurvedic/herbal products, veterinary feed supplements, and homecare items. Its robust financial performance, with a notable increase in profit after tax (PAT) and revenue in recent fiscal years, has likely contributed to the positive investor sentiment.
What’s Next for Investors?
With the IPO closing today, investors who have applied will now await the allotment finalization, which is tentatively scheduled for Monday, June 23, 2025. Refunds for non-allottees and the crediting of shares to successful bidders’ Demat accounts are expected to occur on Tuesday, June 24, 2025. The shares of Influx Healthtech are slated to be listed on the NSE SME platform on Wednesday, June 25, 2025.
As the company prepares for its listing, all eyes will be on its performance in the secondary market, which will further affirm investor confidence in this growing healthcare manufacturing